A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective

European Journal of Health Economics

Volumn 17, Issue 3, 2016, Pages 287-304

  Tolley, Keith ^a   Kemmett, Danny ^b   Thybo, Signe ^c   Nasr, Ruth ^c   Smethurst, Helen ^d  

^a Tolley Health Economics   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c LEO Pharma   (United Kingdom)

^d Decision Resources Group   (United Kingdom)

Author keywords

Actinic keratosis; Cost effectiveness; ICER; Ingenol mebutate gel

Indexed keywords

CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; INGENOL MEBUTATE; SALICYLIC ACID; 3-INGENYL ANGELATE; DITERPENE; KERATOLYTIC AGENT;

ACTINIC KERATOSIS; ADULT; ARTICLE; BLISTER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CRYOTHERAPY; DISEASE CLEARANCE; DRUG COST; DRUG EFFICACY; FACE; HEALTH CARE UTILIZATION; HUMAN; INFLAMMATION; PAIN; PRIORITY JOURNAL; RECURRENT DISEASE; SCALP; ULCER; UNITED KINGDOM; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; KERATOSIS, ACTINIC; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; SCOTLAND; STATISTICAL MODEL; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; CRYOTHERAPY; DICLOFENAC; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; KERATOLYTIC AGENTS; KERATOSIS, ACTINIC; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SALICYLIC ACID; SCOTLAND; TREATMENT OUTCOME;

EID: 84925435159     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-015-0679-8     Document Type: Article

References (43)

1. Marks, R., Foley, P., Goodman, G., Hage, B.H., Selwood, T.S.: Spontaneous remission of solar keratoses: the case for conservative management. Br. J. Dermatol. 115(6), 649–655 (1986)
2. Primary Care Dermatology Society: Actinic keratosis (syn. solar keratosis). http://www.pcds.org.uk/image-atlas/a-z-of-diagnosis/50-image-atlas-detailed-articles/73-actinic-keratosis (2010)
3. Harvey, I., Frankel, S., Marks, R., Shalom, D., Nolan-Farrell, M.: Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br. J. Cancer 74(8), 1302–1307 (1996)
4. Tinghog, G., Carlsson, P., Synnerstad, I., Rosdahl, I.: Societal cost of skin cancer in Sweden in 2005. Acta Derm. Venereol. 88(5), 467–473 (2008). doi:10.2340/00015555-0523
5. Morris, S., Cox, B., Bosanquet, N.: Cost of skin cancer in England. European J. Health Econ. 10(3), 267–273 (2009). doi:10.1007/s10198-008-0127-0
6. Cancer Research UK: Skin cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/mortality/#source14 (2013). Accessed July 2013
7. Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Eide, M.J., Bingham, S.F.: Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial. Cancer 115(11), 2523–2530 (2009). doi:10.1002/cncr.24284
8. Einspahr, J.G., Stratton, S.P., Bowden, G.T., Alberts, D.S.: Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41(3):269–285 (2002). pii: S1040842801001858
9. Feldman, S.R., Fleischer Jr, A.B.: Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201–207 (2011)
10. ®). Meda Pharmaceuticals. SMC No. (385/07). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/385_07_imiquimod_cream__Aldara_/imiquimod_cream__Aldara_ (2008). Accessed July 2013
11. ®). Galderma Ltd. SMC No. (50/03) Available at: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/Methyl_amonolevulinate__Metvix_cream__174___for_actinic_keratoses/Methyl_aminolevulinate__Metvix_cream__ (2003). Accessed July 2013
12. ®). SMC No. (811/12) (2012)
13. NHS Scotland, S.D.S.: Solar (Actinic) keratoses and Bowen’s disease. Dermatology referral and management pathway (2010)
14. eMC: Summary of Product Characteristics: Actikerall 5 mg/g + 100 mg/g Cutaneous Solution. http://www.medicines.org.uk/EMC/medicine/24614/SPC/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution/ (2011). Accessed July 2013
15. eMC: Summary of Product Characteristics: Solaraze. http://www.medicines.org.uk/emc/medicine/21229 (2012). Accessed July 2013
16. eMC: Summary of Product Characteristics: Efudix Cream. http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream/ (2011). Accessed July 2013
17. Yentzer, B., Hick, J., Williams, L., Inabinet, R., Wilson, R., Camacho, F.T., Russell, G.B., Feldman, S.R.: Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch. Dermatol. 145(2), 203–205 (2009)
18. Wilson, E.C.: Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 28(11), 1055–1064 (2010)
19. Jeffes, E.W., McCullough, J.L., Weinstein, G.D., Fergin, P.E., Nelson, J.S., Shull, T.F., Simpson, K.R., Bukaty, L.M., Hoffman, W.L., Fong, N.L.: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727–732 (1997)
20. Taub, A.F., Garretson, C.B.: A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J. Drugs Dermatol. 10(9), 1049–1056 (2011)
21. Szeimies, R.M., Karrer, S., Sauerwald, A., Landthaler, M.: Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192(3), 246–251 (1996)
22. Ulrich, M., Völker-Call, M., Lange-Asschenfeldt, S., Röwert-Huber, J., Østerdal, M.L., Skak, K., Skov, T., Stockfleth, E.: Biological effects of ingenol mebutate gel, 0.05%, for the treatment of actinic keratosis as assessed by reflectance confocal microscopy. Poster presented at American Academy of Dermatology Summer Academy Meeting Aug 15–19 2012, Boston, MA. USA. (2) (2012)
23. Lebwohl, M., Swanson, N., Anderson, L.L., Melgaard, A., Xu, Z., Berman, B.: Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010–1019 (2012)
24. Muston, D., Downs, A., Rives, V.: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 20(5), 266–275 (2009)
25. ISD Scotland: Prescription Cost Analysis for financial year 2011/12. http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/data-tables.asp (2012)
26. Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.: NICE DSU technical support document 5: Evidence synthesis in the baseline natural history model. http://www.nicedsu.org.uk/TSD5%20Baseline.final%20report.08.05.12.pdf (2011)
27. Krawtchenko, N., Roewert-Huber, J., Ulrich, M., Mann, I., Sterry, W., Stockfleth, E.: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl 2), 34–40 (2007)
28. eMC: Summary of Product Characteristics: Picato 150 mcg/g Gel. http://www.medicines.org.uk/emc/medicine/27246/SPC/Picato+150+mcg+g+Gel/ (2012). Accessed July 2013
29. Stockfleth, E., Kerl, H., Zwingers, T., Willers, C.: Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101–1108 (2011)
30. Littenberg, B., Partilo, S., Licata, A., Kattan, M.W.: Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med. Decis. Making 23(6), 480–488 (2003). doi:10.1177/0272989X03259817
31. Chen, S.C., Bayoumi, A.M., Soon, S.L., Aftergut, K., Cruz, P., Sexton, S.A., McCall, C.O., Goldstein, M.K.: A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9(2), 160–168 (2004). doi:10.1046/j.1087-0024.2003.09112.x
32. MIMS: Monthly Index of Medical Specialities (MIMS). Haymarket Medical Media, London (July 2012)
33. Thomas, K.S., Keogh-Brown, M.R., Chalmers, J.R., Fordham, R.J., Holland, R.C., Armstrong, S.J., Bachmann, M.O., Howe, A.H., Rodgers, S., Avery, A.J., Harvey, I., Williams, H.C.: Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess 10(25), iii, ix-87 (2006). doi:02-12-03 [pii]
34. Curtis, L.: Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, Canterbury (2011)
35. ISD Scotland: Acute medical costs R044X: Specialty group costs—consultant outpatients (2011)
36. Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000)
37. Briggs, A.H., O’Brien, B.J., Blackhouse, G.: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public Health 23, 377–401 (2002)
38. ®) SMC No. (851/13). http://www.scottishmedicines.org.uk/files/advice/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf (2013). Accessed Aug 2013
39. Scottish Medicines Consortium: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). (2012)
40. Jorizzo, J., Dinehart, S., Matheson, R., Moore, J.K., Ling, M., Fox, T.L., McRae, S., Fielder, S., Lee, J.H.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265–268 (2007)
41. Gebauer, K., Brown, P., Varigos, G.: Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol. 44(1), 40–43 (2003)
42. Weinstock, M.A., Lee, K.C., Chren, M.M., Marcolivio, K.: Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J. Am. Acad. Dermatol. 61(2), 207–215 (2009)
43. European Dermatology Forum: Guideline on Actinic Keratoses (update) (2011)